Clinical Trial Update: A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Pfizer's RSVpreF vaccine for safety, tolerability, and immunogenicity in adults at high risk of severe RSV disease has completed with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSVpreF

Snippet

Sponsor: Pfizer | Conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV) | Phase 3 | Status: COMPLETED | Results posted: 2025-08-08